Journal of Cardiac Failure
Volume 17, Issue 4 , Pages 265-271, April 2011

Response to Inhaled Nitric Oxide Predicts Survival in Patients With Pulmonary Hypertension

  • Richard A. Krasuski, MD

      Affiliations

    • Director of Adult Congenital Heart Disease Service, Division of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH
    • Corresponding Author InformationReprint requests: Richard A. Krasuski, MD, Desk J2-4, Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. Tel: (210) 445-7433; Fax: (210) 445-6163.
  • ,
  • Ganesh P. Devendra, BA

      Affiliations

    • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • ,
  • Stephen A. Hart, BS

      Affiliations

    • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • ,
  • Andrew Wang, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC
  • ,
  • J. Kevin Harrison, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, DukeUniversity Medical Center, Durham, NC
  • ,
  • Thomas M. Bashore, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, DukeUniversity Medical Center, Durham, NC

Received 29 September 2010; received in revised form 18 November 2010; accepted 22 November 2010. published online 24 January 2011.

Abstract 

Objective

To examine the ability of vasodilator response to predict survival in a diverse cohort of patients with pulmonary hypertension (PH).

Patients & Methods

A total of 214 consecutive treatment-naive patients referred for invasive PH evaluation were enrolled between November 1998 and December 2008. Vasoreactivity was assessed during inhalation of 40 parts per million nitric oxide (iNO) and vasodilator responders were defined as those participants who achieved a mean pulmonary artery pressure (PAP) of ≤ 40 mm Hg and a drop in mean PAP ≥ the median for the cohort (13%). Kaplan-Meier analysis and Cox proportional hazards modeling were used to identify predictors of survival.

Results

There were 51 deaths (25.9%) over a mean follow-up period of 2.3 years. Kaplan-Meier analysis demonstrated that vasodilator responders had significantly improved survival (P < .01). Vasodilator responders had improved survival regardless of whether or not they had idiopathic or nonidiopathic PH (P = .02, P < .01) or whether or not they had Dana Point class 1 or non-Dana Point class 1 PH (P < .01, P = .01). In multivariate modeling, advanced age, elevated right atrial pressure, elevated serum creatinine, and worsened functional class significantly predicted shorter survival (P = .01, P = .01, P = .01, P < .01), whereas vasodilator response predicted improved survival (P = .01).

Conclusions

Vasodilator responsiveness to iNO is an important method of risk stratifying PH patients, with results that apply regardless of clinical etiology.

Key Words: Vasodilator challenge, pulmonary hypertension, pulmonary arterial hypertension, mortality

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 See page 270 for disclosure information.

PII: S1071-9164(10)01230-3

doi:10.1016/j.cardfail.2010.11.010

Journal of Cardiac Failure
Volume 17, Issue 4 , Pages 265-271, April 2011